Loading...
Cizzle Biotechnology Holdings Plc
CIZ.L•LSE
Healthcare
Biotechnology
£1.40
£0.00(0.00%)

Over the last four quarters, Cizzle Biotechnology Holdings Plc's revenue moved from $0.00 in Q2 2023 to $0.00 in Q2 2024. Operating income in Q2 2024 was -$299.00, with a strong operating margin of N/A. Despite fluctuations in R&D and SG&A expenses, EBITDA for Cizzle Biotechnology Holdings Plc remained robust at -$2.84M, reflecting operational efficiency. Net income dropped to -$1411.00, with an EPS of $0.00. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan